<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04839926</url>
  </required_header>
  <id_info>
    <org_study_id>NH101-11</org_study_id>
    <nct_id>NCT04839926</nct_id>
  </id_info>
  <brief_title>A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Phase I Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of CY150112 After Single Oral Administration in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Nhwa Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Nhwa Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of single ascending dose study is to evaluate the safety and&#xD;
      tolerability of CY150112 after single oral administration of different doses in healthy&#xD;
      Chinese subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single administration, double-blinded, placebo-controlled (2 subjects in each group will take&#xD;
      placebo,8 subjects in each group will take CY150112) and 6 dose groups (0.5mg, 1.5mg, 4.5mg,&#xD;
      10mg, 18mg and 24mg).&#xD;
&#xD;
      This study comprises a screening period (between signing of the informed consent form and Day&#xD;
      -1), baseline period (Day -1), treatment period (Days 1-5) and follow-up period(Days 12 or 7&#xD;
      days after discharge ).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>pre-dose（within1hour）,0.25,0.5,1,1.5,2,2.5,3,4,6,8,12,24,48,96hours post-dose</time_frame>
    <description>Incidence of Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>pre-dose（within1hour）,0.25,0.5,1,1.5,2,2.5,3,4,6,8,12,24,48,96hours post-dose</time_frame>
    <description>Maximum (peak) observed drug serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>pre-dose（within1hour）,0.25,0.5,1,1.5,2,2.5,3,4,6,8,12,24,48,96hours post-dose</time_frame>
    <description>Area under the concentration-time curve from time zero (pre-dose) to the time of the dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>pre-dose（within1hour）,0.25,0.5,1,1.5,2,2.5,3,4,6,8,12,24,48,96hours post-dose</time_frame>
    <description>Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCex</measure>
    <time_frame>pre-dose（within1hour）,0.25,0.5,1,1.5,2,2.5,3,4,6,8,12,24,48,96hours post-dose</time_frame>
    <description>Extrapolation percentage of AUC0-∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>pre-dose（within1hour）,0.25,0.5,1,1.5,2,2.5,3,4,6,8,12,24,48,96hours post-dose</time_frame>
    <description>Time of occurrence of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>pre-dose（within1hour）,0.25,0.5,1,1.5,2,2.5,3,4,6,8,12,24,48,96hours post-dose</time_frame>
    <description>Biological half life correlated with the elimination rate constant (kel) of semi-logarithmic concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd</measure>
    <time_frame>pre-dose（within1hour）,0.25,0.5,1,1.5,2,2.5,3,4,6,8,12,24,48,96hours post-dose</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>pre-dose（within1hour）,0.25,0.5,1,1.5,2,2.5,3,4,6,8,12,24,48,96hours post-dose</time_frame>
    <description>Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>pre-dose（within1hour）,0.25,0.5,1,1.5,2,2.5,3,4,6,8,12,24,48,96hours post-dose</time_frame>
    <description>Elimination rate constant</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>0.5mg CY150112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral CY150112 while fasting on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5mg CY150112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral CY150112 while fasting on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4.5mg CY150112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral CY150112 while fasting on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10mg CY150112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral CY150112 while fasting on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18mg CY150112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral CY150112 while fasting on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24mg CY150112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral CY150112 while fasting on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5mg CY150112</intervention_name>
    <description>single oral CY150112 while fasting on day 1.</description>
    <arm_group_label>0.5mg CY150112</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.5mg CY150112</intervention_name>
    <description>single oral CY150112 while fasting on day 1.</description>
    <arm_group_label>1.5mg CY150112</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4.5mg CY150112</intervention_name>
    <description>single oral CY150112 while fasting on day 1.</description>
    <arm_group_label>4.5mg CY150112</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10mg CY150112</intervention_name>
    <description>single oral CY150112 while fasting on day 1.</description>
    <arm_group_label>10mg CY150112</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18mg CY150112</intervention_name>
    <description>single oral CY150112 while fasting on day 1.</description>
    <arm_group_label>18mg CY150112</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>24mg CY150112</intervention_name>
    <description>single oral CY150112 while fasting on day 1.</description>
    <arm_group_label>24mg CY150112</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male/female subjects are 18&lt;age ≤45 years of age when signing the informed consent.&#xD;
&#xD;
          2. Male Subjects with body weight of ≥50.0kg ，and female Subjects with body weight of&#xD;
             ≥45.0kg and BMI (body mass index) of 18.5≤ and &lt;28.0 at screening examination.&#xD;
&#xD;
          3. After detailed explanations of study objectives, contents and procedures, and possible&#xD;
             risks, subjects are aware of all relevant information related to this study and have&#xD;
             signed the written informed consent form voluntarily.&#xD;
&#xD;
          4. Subjects are able to communicate well with researchers, be willing and able to comply&#xD;
             with the lifestyle restrictions stipulated during this study period, and cooperate to&#xD;
             complete this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The investigator determined that the subjects' present medical history and past&#xD;
             medical history had any disease or dysfunction that would affect the clinical trial,&#xD;
             including but not limited to diseases of the central nervous system, cardiovascular&#xD;
             system, respiratory system, digestive system, urinary system, endocrine system,&#xD;
             hematological system, etc.&#xD;
&#xD;
          2. There is any surgical condition or disease that may significantly affect the&#xD;
             absorption, distribution, metabolism and excretion of drugs, or may harm to the&#xD;
             subjects participating in the trial; such as history of gastrointestinal operations&#xD;
             (gastrectomy, gastroenterostomy, enterectomy, etc.), urinary tract obstruction or&#xD;
             dysuria, gastroenteritis, digestive tract ulcers, history of gastrointestinal&#xD;
             bleeding, etc.&#xD;
&#xD;
          3. Subjects with past history of allergy to drugs or allergic disease.&#xD;
&#xD;
          4. Subjects with currently or past history of mental disorders and brain functional&#xD;
             disorders.&#xD;
&#xD;
          5. According to the Columbia suicide severity scale (C-SSRS), subjects were at risk of&#xD;
             suicide or were at risk of suicide based on the clinical judgment of the researchers,&#xD;
             or with past history of self-injurious behavior.&#xD;
&#xD;
          6. Subjects have history of drug abuse or positive urine drug tests at screening within 1&#xD;
             year prior.&#xD;
&#xD;
          7. Subjects have history of alcohol abuse(i.e.,criteria are per week consumption more&#xD;
             than 14 standard units(1 unit =360mL beer or 45mL 40% alcohol of Chinese liquor or&#xD;
             150mL wine)or positive alcohol breath tests at screening within 1 year prior.&#xD;
&#xD;
          8. Average amount of daily smoking&gt;5 cigarettes at screening 3 months prior.&#xD;
&#xD;
          9. Those who have special requirements for food, cannot follow a uniform diet or have&#xD;
             difficulty swallowing.&#xD;
&#xD;
         10. Female subjects who are pregnant and lactating ; and those who refuse to use effective&#xD;
             non-drug contraceptive measures (such as abstinence, intrauterine device) or have&#xD;
             planned to donate sperm or ovum throughout the study period and within 3 months after&#xD;
             the end of the study.&#xD;
&#xD;
         11. Abnormal vital signs, lab and ECG indicators, as determined by the researcher, and&#xD;
             clinically significant (e.g., male QTC &gt; 450ms female &gt; 470ms,corrected by Friericia&#xD;
             ).&#xD;
&#xD;
         12. Subjects who resting heart rate &lt;55 beats/min or &gt;100 beats/min; systolic blood&#xD;
             pressure &lt;90mmHg or &gt;140mmHg; diastolic blood pressure &lt;60mmHg or &gt;90mmHg.&#xD;
&#xD;
         13. Subjects who hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCV-Ab), or&#xD;
             HIV antibody (HIV-Ab), or syphilis serum reaction (TRUST) is non-negative.&#xD;
&#xD;
         14. Subjects who glutamic-pyruvic transaminase(ALT), creatinine (Cr), urea nitrogen (BUN)&#xD;
             exceeding the normal upper limit or the level of serum prolactin is 2 times higher&#xD;
             than the normal upper limit.&#xD;
&#xD;
         15. Subjects who participated in any clinical trial within 3 months before medication.&#xD;
&#xD;
         16. Subjects have history of blood donations of 400 mL within 3 months before enrollment;&#xD;
             200 mL within 1 month before enrollment; or have history of using blood products.&#xD;
&#xD;
         17. Subjects who had a history of surgery within 3 months prior to enrollment, or did not&#xD;
             recover from surgery, or had an expected surgical plan during the study period.&#xD;
&#xD;
         18. Subjects who had taken any drugs, including prescription and over-the-counter drugs&#xD;
             within 2 weeks prior to enrollment.&#xD;
&#xD;
         19. Subjects who directly related to this clinical trial.&#xD;
&#xD;
         20. Subjects have poor compliance or other problems that the researchers believe that it&#xD;
             is not suitable for participating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hua Fang li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Fang li, MD</last_name>
    <phone>021-34773107</phone>
    <email>lhlh_5@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Yan, Research Doctor</last_name>
    <phone>021-34773107</phone>
    <email>lhlh_5@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hua Fang li, MD</last_name>
      <phone>021-34773107</phone>
      <email>lhlh_5@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Li Yan, Research Doctor</last_name>
      <phone>021-34773107</phone>
      <email>lhlh_5@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hua Fang Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Yan, Research Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety, Tolerability,Pharmacokinetics</keyword>
  <keyword>CY150112</keyword>
  <keyword>Single Ascending Dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

